Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
04/2002
04/25/2002US20020048801 Peptide with enzymatic activity; for use as diagnostic tools in detecting cancer and cardiovascular and liver disorders
04/25/2002US20020048800 Myosin-like gene expressed in human heart and muscle
04/25/2002US20020048794 Polypeptides for use in the diagnosis and treatment of skin disorders, cancer, vision and demyelination defects, inflammation, glomerculonephritis, Kaposi's sarcoma, angiogenesis, sarcoidosis, osteoarthritis and aneurysm
04/25/2002US20020048792 Methods and materials for regulated production of proteins
04/25/2002US20020048791 Nucleotide sequences coding preferential polypeptides; for use in the treatment of dietetics, diabetes, anxiety, hypertension, drug dependence, congestive heart failure, cardiovascular disorders, tumors and nervous system disorders
04/25/2002US20020048790 Nucleotide sequences coding binding protein for use in the prevention of infections; bactericides
04/25/2002US20020048789 birA
04/25/2002US20020048788 FtsA
04/25/2002US20020048787 Peptides; for use in development of human therapeutics and diagnostic testing
04/25/2002US20020048786 Nucleotide sequences for use in the treatment of infections, arthritis, karposi's sarcoma, allergies, asthma, nervous system and autoimmune diseases
04/25/2002US20020048785 Novel polypeptides within the tumor necrosis factor receptor superfamily and uses therefor
04/25/2002US20020048777 Nucleotide sequences for use in therapy, monitoring and screning preferential tumors
04/25/2002US20020048764 Human PEM as a target for birth contol and treatment of Alzheimer's disease
04/25/2002US20020048763 Nucleotide sequences for use in the detection of transcription patterns in preferential tissues
04/25/2002US20020048748 Controlling human lymphocyte leukemia/lymphoma viruses immunodeficiency virus; obtain human, administer viricide and interleukin, monitor human for adjust in viral activity
04/25/2002US20020048599 Method for increasing tissue perfusion by co-administration of an agent that increases cGMP synthesis and an agent that inhibits cGMP degradation
04/25/2002US20020048586 Therapeutic compositions that alter the immune response
04/25/2002US20020048585 Decreasing syndecan-4 expression, level, or activity
04/25/2002US20020048584 Patients that are treated with HAART are then treated with an intensification regimen wherein hydroxyurea and didanosine (ddI) are given; followed by addition of compounds, such as OKT3 and IL-2, that activate latently infected cells
04/25/2002US20020048581 Modulating Protein Kinase C beta; useful in the treatment of insulin-related disorders, e.g., hypertension.
04/25/2002US20020048578 Modified version of a therapeutic antibody with affinity for a cell-surface antigen; capable of inducing immunological tolerance to the therapeutic antibody
04/25/2002US20020048577 Methods and devices to modulate the wound response
04/25/2002US20020048576 Enzyme that cleaves a linkage that effects release of a cell-surface protein or carbohydrate and a physiologically acceptable carrier for said enzyme; form suitable for oral administration.
04/25/2002US20020048575 Flavonoid source and an enzyme; effective for inhibiting platelet activity and LDL cholesterol oxidation in a mammal at a dosage of about 30 mg/Kg or less.
04/25/2002US20020048573 Lytic enzymes useful for treating fungal infections
04/25/2002US20020048571 Chimeric polypeptides of serum albumin and uses related thereto
04/25/2002US20020048566 Modulation of cellular apoptosis and methods for treating cancer
04/25/2002US20020048565 Mammalian tolloid-like gene and protein
04/25/2002US20020048562 Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
04/25/2002US20020046750 Inhaled insulin dosage control delivery enhanced by controlling total inhaled volume
04/25/2002DE10051716A1 Composition for treating viral infections, especially caused by retro- or hepatitis viruses, comprises proteosome inhibitor that prevents release, maturation or replication
04/25/2002DE10042853A1 Nachweis und Beeinflußung der Expression oder Funktion von CD95/CD95L bei Infektionen Detecting and influencing the expression or function of CD95 / CD95L in infections
04/25/2002CA2818654A1 Pregnancy-associated plasma protein-a2 (papp-a2)
04/25/2002CA2464121A1 Pregnancy-associated plasma protein-a2 (papp-a2)
04/25/2002CA2464092A1 Electroprocessing in drug delivery and cell encapsulation
04/25/2002CA2453140A1 Inhibition of the interaction between oxidized proteins and cd36 or the active mechanism thereof
04/25/2002CA2426460A1 Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
04/25/2002CA2426403A1 Isocitrate dehydrogenase, gene thereof, and use of the same in the treatment of obesity, hyperlipidemia, and fatty liver in lipid biosynthesis
04/25/2002CA2426381A1 Cell damage inhibitor
04/25/2002CA2426371A1 Human tuberoinfundibular peptide of 39 residues
04/25/2002CA2426312A1 Compositions and methods for modulating rsv infection and immunity
04/25/2002CA2426198A1 Zipper protein kinase and uses thereof
04/25/2002CA2425963A1 Human kinases
04/25/2002CA2425804A1 Urotensin-ii agonists and antagonists
04/25/2002CA2425727A1 Methods and compositions for promoting the maturation of monocytes
04/25/2002CA2425669A1 Mutations in the ferroportin 1 gene associated with hereditary haemochromatosis
04/25/2002CA2425662A1 Osteopontin-coated surfaces and methods of use
04/25/2002CA2425522A1 Ribavirin-pegylated interferon alfa hcv combination therapy
04/25/2002CA2425221A1 Protein c or activated protein c-like molecules
04/25/2002CA2424371A1 Agonistic monoclonal antibody fragments
04/25/2002CA2423933A1 Pharmaceutically active sulfanilide derivatives
04/25/2002CA2423792A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
04/25/2002CA2423073A1 Recombinant antibody fragments as autoantibody antagonists
04/25/2002CA2419388A1 Substituted dipeptides as growth hormone secretagogues
04/25/2002CA2405906A1 Remedies or preventives for rheumatoid arthritis
04/24/2002EP1199566A1 Methods of screening affinity marker libraries
04/24/2002EP1199363A1 Phosphorylation modifications of apoptin
04/24/2002EP1199362A2 Immunoregulator from the family designated 'leukocyte immunoglobulin-like receptors' (LIR)
04/24/2002EP1199361A2 Glycoprotein hormone receptor molecules. Their uses
04/24/2002EP1199360A2 Active and inactive CC-chemokine receptors and nucleic acid molecules encoding said receptor
04/24/2002EP1199080A2 Co-administration of interleukin-3 mutants with colony stimulating factors
04/24/2002EP1198589A1 Tenascin-c nucleic acid ligands
04/24/2002EP1198581A1 Structural protein of adeno-associated virus with modified antigenicity, its production and its use
04/24/2002EP1198570A1 Monomeric protein of the tgf-beta family
04/24/2002EP1198568A1 Compositions and methods for the treatment of immune related diseases
04/24/2002EP1198563A2 Novel fibroblast growth factor and nucleic acids encoding same
04/24/2002EP1198560A2 Mammalian adhesion protease peptides
04/24/2002EP1198479A1 Neovascular-targeted immunoconjugates
04/24/2002EP1198478A1 Somatostatin analogs and their use for the treatment of cancer
04/24/2002EP1198477A1 Prolactin-releasing peptide and method for regulating autonomic functions and treating pain
04/24/2002EP1198475A1 Highly purified cytokine activating factor and methods of use
04/24/2002EP1198473A1 Pseudomycin amide and ester analogs
04/24/2002EP1198472A1 Amine-modified pseudomycin compounds
04/24/2002EP1198471A1 Process for deacylation of lipodepsipeptides
04/24/2002EP1198470A1 Pseudomycin prodrugs
04/24/2002EP1198469A2 A member of the frzb family, frazzled
04/24/2002EP1198256A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery
04/24/2002EP1198255A1 Identification of compounds that modify transcriptional responses to hypoxia
04/24/2002EP1198251A1 Combination of an anti-ep-cam antibody with a chemotherapeutic agent
04/24/2002EP1198250A1 Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
04/24/2002EP1198247A2 Compositions and methods related to claudin-7
04/24/2002EP1198242A1 Autologous thrombin
04/24/2002EP1198241A1 Novel proteins
04/24/2002EP1198240A2 Tissue regenerating agent
04/24/2002EP1198239A1 Methods employing bacterial toxin-antitoxin systems for killing eukaryotic cells
04/24/2002EP1198238A2 Gene encoding nade, p75ntr -associated cell death executor and uses thereof
04/24/2002EP1198235A1 Method of promoting bone growth with hyaluronic acid and growth factors
04/24/2002EP1167527A9 Processed human chemokines PHC-1 and PHC-2
04/24/2002EP1156787A4 Oxadiazole compounds and compositions for delivering active agents
04/24/2002EP0876399B1 Peptides and uses thereof for therapy of celiac diseases
04/24/2002EP0863911B1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF raf GENE EXPRESSION
04/24/2002EP0851768B1 Interactive molecular conjugates
04/24/2002EP0820299B1 Formulations for il-12
04/24/2002EP0788388B1 Device for aerosolized delivery of peptide drugs
04/24/2002EP0785951B1 Tc or re radiolabelled somatostatin analogs
04/24/2002EP0765126B1 Therapeutic food composition and method to diminish blood sugar fluctuations
04/24/2002EP0752008B1 Dna mutagenesis by random fragmentation and reassembly
04/24/2002CN1346406A Human ubiquitin ligase E3 for the modulation of NF-kappa 8
04/24/2002CN1346371A Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
04/24/2002CN1346370A Polypeptides involved in immune response